IPCIQ.US Intellipharmaceutics International Inc.
- Market cap
- USD 4.96M
- P/E
- -
- P/B
- -
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Nov 2022.
Is IPCIQ.US undervalued?
Graham numberThe Graham number of Intellipharmaceutics International Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Intellipharmaceutics International Inc. fundamental analysis
No fundamental analysis for Intellipharmaceutics International Inc. yet.
Intellipharmaceutics International Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Intellipharmaceutics International Inc.
Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Foca…
Full company profileIntellipharmaceutics International Inc. financial statements
Intellipharmaceutics International Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 |
|---|---|---|
| Income Statement | ||
| Revenue | 0.00 | 65.7K |
| Gross Profit | 0.00 | - |
| Operating Income | -4.17M | -2.85M |
| EBITDA | -4.45M | -2.39M |
| Net Income | -5.15M | -2.89M |
| EPS | -0.16 | -0.09 |
| Balance Sheet | ||
| Total Assets | 2.10M | 1.43M |
| Total Liabilities | 10.3M | 12.0M |
| Shareholders' Equity | -8.16M | -10.6M |
| Cash & Short-term Investments | 772K | 83.7K |
| Cash Flow | ||
| Operating Cash Flow | -2.46M | -1.39M |
| Capital Expenditure | 0.00 | 0.00 |
| Free Cash Flow | -2.46M | -1.39M |
| Ratios | ||
| ROA | -245.4% | -202.0% |
| Net Profit Margin | - | -4,400.6% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Intellipharmaceutics International Inc. dividends
Intellipharmaceutics International Inc. has not paid dividends in the last 5 fiscal years.
Last stock split: 1:10 on Sep 14, 2018.
Who owns Intellipharmaceutics International Inc.
- Insiders 1.76%
- Institutions 0.00%
- Public & others 98.24%
- Shares outstanding 33.1M
- Free float 33.1M
Intellipharmaceutics International Inc. company profile
- Company name
- Intellipharmaceutics International Inc.
- Ticker
- IPCIQ.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 11
- Fiscal year end
- November
- Address
- 30 Worcester Road, Toronto, ON, Canada, M9W 5X2
- Phone
- 416 798 3001
- Website
- intellipharmaceutics.com
About Intellipharmaceutics International Inc.
Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. In addition, it provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. Further, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. Intellipharmaceutics International Inc. was founded in 1998 and is based in Toronto, Canada.
Intellipharmaceutics International Inc. management
4- Dr. Isa Odidi MBA, Ph.D.Co-Founder, Chairman of the Board, CEO & Co-Chief Scientific Officer · born 1958
- Dr. Amina Odidi Ph.D.President, COO, Co-Chief Scientific Officer, Acting CFO & Executive Director · born 1960
- Dr. Patrick N. Yat Ph.D.Vice-President of Chemistry & Analytical Services · born 1958
- Fazayill ShaideenController